Trials (Masaryk Memorial Cancer Institute) - Revision history

Francine: /* Trials: How to access */

2025-12-14T14:10:36Z

Trials: How to access

← Older revision		Revision as of 14:10, 14 December 2025
Line 7:		Line 7:
	Go back to [[Masaryk Memorial Cancer Institute]] page		Go back to [[Masaryk Memorial Cancer Institute]] page

	=== Trials: How to ~~access~~ ===		=== Trials: How to participate ===
	'''Contact information:''' [https://www.mou.cz/klinicke-studie/t1520 Click here to access].		'''Contact information:''' [https://www.mou.cz/klinicke-studie/t1520 Click here to access].

Francine at 13:40, 14 December 2025

2025-12-14T13:40:50Z

← Older revision		Revision as of 13:40, 14 December 2025
Line 6:		Line 6:
	<span style="display:none">cancer center</span>		<span style="display:none">cancer center</span>
	Go back to [[Masaryk Memorial Cancer Institute]] page		Go back to [[Masaryk Memorial Cancer Institute]] page

			=== Trials: How to access ===
			'''Contact information:''' [https://www.mou.cz/klinicke-studie/t1520 Click here to access].


	'''NCTID''': NCT05603351		'''NCTID''': NCT05603351
Line 105:		Line 109:
	<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>		<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
	<span style="display:none">hasCancerType::unknown</span>		<span style="display:none">hasCancerType::unknown</span>
			<span style="display:none">isTrial</span>

Lucas: Update categories.

2025-12-06T12:42:00Z

Update categories.

← Older revision		Revision as of 12:42, 6 December 2025
Line 84:		Line 84:
	<span style="display:none">hasTrialTitle::Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)</span>		<span style="display:none">hasTrialTitle::Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)</span>
	<span style="display:none">hasTrialTitle::E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer</span>		<span style="display:none">hasTrialTitle::E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer</span>
			<span style="display:none">hasCancerType::C00-D48: All neoplasms</span>
			<span style="display:none">hasCancerType::C00-C97: All cancer types</span>
			<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
			<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
			<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
			<span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
			<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
			<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
			<span style="display:none">hasCancerType::C50: Breast cancer</span>
			<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
			<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
			<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
			<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
			<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
			<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
			<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
			<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
			<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
			<span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
			<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
			<span style="display:none">hasCancerType::unknown</span>

Lucas: Update categories.

2025-12-02T14:00:07Z

Update categories.

← Older revision		Revision as of 14:00, 2 December 2025
Line 1:		Line 1:
	{{forpatients}}		<span style="display:none">forpatients</span>
	{{forproviders}}		<span style="display:none">forproviders</span>
	{{forresearchers}}		<span style="display:none">forresearchers</span>
	{{czechrepubliccountry}}		<span style="display:none">czechrepubliccountry</span>
	{{hospital}}		<span style="display:none">hospital</span>
	{{cancer center}}		<span style="display:none">cancer center</span>
	Go back to [[Masaryk Memorial Cancer Institute]] page		Go back to [[Masaryk Memorial Cancer Institute]] page

Line 77:		Line 77:
	'''Recruitment Status''': COMPLETED		'''Recruitment Status''': COMPLETED
	'''Condition''': Breast Cancer/		'''Condition''': Breast Cancer/
			<span style="display:none">hasTrialTitle::Prostate Cancer Screening With Abbreviated MRI Protocol</span>
			<span style="display:none">hasTrialTitle::Ideal Marker for Targeted Axillary Dissection</span>
			<span style="display:none">hasTrialTitle::FMISO-based Adaptive Radiotherapy for Head and Neck Cancer</span>
			<span style="display:none">hasTrialTitle::Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence</span>
			<span style="display:none">hasTrialTitle::Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma</span>
			<span style="display:none">hasTrialTitle::Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)</span>
			<span style="display:none">hasTrialTitle::E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer</span>

Francine at 12:05, 2 December 2025

2025-12-02T12:05:39Z

← Older revision		Revision as of 12:05, 2 December 2025
Line 2:		Line 2:
	{{forproviders}}		{{forproviders}}
	{{forresearchers}}		{{forresearchers}}
	{{~~czech republic~~}}		{{czechrepubliccountry}}
	{{hospital}}		{{hospital}}
	{{cancer center}}		{{cancer center}}

Victor at 18:47, 6 November 2024

2024-11-06T18:47:32Z

← Older revision		Revision as of 18:47, 6 November 2024
Line 3:		Line 3:
	{{forresearchers}}		{{forresearchers}}
	{{czech republic}}		{{czech republic}}
			{{hospital}}
			{{cancer center}}
	Go back to [[Masaryk Memorial Cancer Institute]] page		Go back to [[Masaryk Memorial Cancer Institute]] page

Victor at 23:01, 5 November 2024

2024-11-05T23:01:15Z

← Older revision		Revision as of 23:01, 5 November 2024
Line 2:		Line 2:
	{{forproviders}}		{{forproviders}}
	{{forresearchers}}		{{forresearchers}}
			{{czech republic}}
	Go back to [[Masaryk Memorial Cancer Institute]] page		Go back to [[Masaryk Memorial Cancer Institute]] page

Francine at 14:03, 4 January 2024

2024-01-04T14:03:58Z

← Older revision		Revision as of 14:03, 4 January 2024
Line 15:		Line 15:
	'''Condition''': Prostate Cancer		'''Condition''': Prostate Cancer
	'''NCTID''': NCT04580251		'''NCTID''': NCT04580251
	'''Title''': Ideal Marker for Targeted Axillary Dissection		'''Title''': [[hasTrialTitle::Ideal Marker for Targeted Axillary Dissection]]
	'''Study Summary''': A multicentre prospective comparative study, comparing the use of various markers (magnetic marker Magseed, iodine seed 125I, carbon suspension) for marking a pathological lymph node in patients with breast carcinoma prior to neoadjuvant therapy and subsequent surgical treatment consisting of targeted axillary dissection.		'''Study Summary''': A multicentre prospective comparative study, comparing the use of various markers (magnetic marker Magseed, iodine seed 125I, carbon suspension) for marking a pathological lymph node in patients with breast carcinoma prior to neoadjuvant therapy and subsequent surgical treatment consisting of targeted axillary dissection.
	'''Sponsor''': University Hospital Ostrava		'''Sponsor''': University Hospital Ostrava
Line 25:		Line 25:
	'''Condition''': Breast Cancer		'''Condition''': Breast Cancer
	'''NCTID''': NCT05348486		'''NCTID''': NCT05348486
	'''Title''': FMISO-based Adaptive Radiotherapy for Head and Neck Cancer		'''Title''': [[hasTrialTitle::FMISO-based Adaptive Radiotherapy for Head and Neck Cancer]]
	'''Study Summary''': Hypoxia occurs in about 80% of head and neck tumors. Based on experimental and clinical data, hypoxia is a useful parameter for pretherapeutic stratification. These radioresistant regions can be detected with FMISO PET/CT. Moreover, hypoxic subvolumes of tumors can be evolving as target volumes for radiotherapy ("dose painting") in hypoxia imaging-based dose escalation.		'''Study Summary''': Hypoxia occurs in about 80% of head and neck tumors. Based on experimental and clinical data, hypoxia is a useful parameter for pretherapeutic stratification. These radioresistant regions can be detected with FMISO PET/CT. Moreover, hypoxic subvolumes of tumors can be evolving as target volumes for radiotherapy ("dose painting") in hypoxia imaging-based dose escalation.
	'''Sponsor''': University Hospital Olomouc		'''Sponsor''': University Hospital Olomouc
Line 35:		Line 35:
	'''Condition''': Head and Neck Cancer		'''Condition''': Head and Neck Cancer
	'''NCTID''': NCT03443856		'''NCTID''': NCT03443856
	'''Title''': Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence		'''Title''': [[hasTrialTitle::Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence]]
	'''Study Summary''': The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma and high risk of recurrence (defined by ypN1-3 and/or R1 status) following neoadjuvant chemotherapy and resection Other study objectives * To investigate the safety and effect of adjuvant immunotherapy on long term oncologic outcomes and quality of life of patients in the stud * To correlate nutritional status assessment on outcomes and quality of life of patients		'''Study Summary''': The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma and high risk of recurrence (defined by ypN1-3 and/or R1 status) following neoadjuvant chemotherapy and resection Other study objectives * To investigate the safety and effect of adjuvant immunotherapy on long term oncologic outcomes and quality of life of patients in the stud * To correlate nutritional status assessment on outcomes and quality of life of patients
	'''Sponsor''': European Organisation for Research and Treatment of Cancer - EORTC		'''Sponsor''': European Organisation for Research and Treatment of Cancer - EORTC
Line 45:		Line 45:
	'''Condition''': Gastric and Esophagogastric Junction Adenocarcinoma		'''Condition''': Gastric and Esophagogastric Junction Adenocarcinoma
	'''NCTID''': NCT04031677		'''NCTID''': NCT04031677
	'''Title''': Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma		'''Title''': [[hasTrialTitle::Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma]]
	'''Study Summary''': This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.		'''Study Summary''': This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
	'''Sponsor''': European Organisation for Research and Treatment of Cancer - EORTC		'''Sponsor''': European Organisation for Research and Treatment of Cancer - EORTC
Line 55:		Line 55:
	'''Condition''': Retroperitoneal Sarcoma		'''Condition''': Retroperitoneal Sarcoma
	'''NCTID''': NCT04921553		'''NCTID''': NCT04921553
	'''Title''': Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)		'''Title''': [[hasTrialTitle::Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)]]
	'''Study Summary''': This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications.		'''Study Summary''': This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications.
	'''Sponsor''': Centre Leon Berard		'''Sponsor''': Centre Leon Berard
Line 65:		Line 65:
	'''Condition''': Cancer		'''Condition''': Cancer
	'''NCTID''': NCT00388726		'''NCTID''': NCT00388726
	'''Title''': E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer		'''Title''': [[hasTrialTitle::E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer]]
	'''Study Summary''': The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally recurrent or metastatic breast cancer.		'''Study Summary''': The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally recurrent or metastatic breast cancer.
	'''Sponsor''': Eisai Inc.		'''Sponsor''': Eisai Inc.

Francine at 14:02, 4 January 2024

2024-01-04T14:02:58Z

← Older revision		Revision as of 14:02, 4 January 2024
Line 5:		Line 5:

	'''NCTID''': NCT05603351		'''NCTID''': NCT05603351
	'''Title''': Prostate Cancer Screening With Abbreviated MRI Protocol		'''Title''': [[hasTrialTitle::Prostate Cancer Screening With Abbreviated MRI Protocol]]
	'''Study Summary''': Prostate cancer is one of the most common malignancies in the male population with incidence and mortality rates comparable to breast cancer in women, but in contrast, a population screening program that would fulfill all the recommended criteria is not yet available. According to international recommendations, the preventive PSA sampling used in clinical practice is not suitable because of the concurrent detection of clinically insignificant carcinomas in a major proportion of tests. These clinically non-significant cancers make up a significant and increasing proportion with age. Detection of non-significant cancers burdens the health care system and patients with the care that has no positive impact on their health. Current preventive serum prostate-specific antigen (PSA) testing does not distinguish benign hyperplasia and nonsignificant carcinoma from clinically significant cancer. It is therefore not suitable for full-scale screening According to current guidelines, magnetic resonance imaging (MRI) is indicated only in patients with an increased risk of cancer for detection or staging after biopsy and is not used for screening. According to recent studies, MRI has detected an increased proportion of significant cancers in the general population compared to screening based on PSA, while fewer clinically insignificant cancers have been detected. In screening, a shorter examination protocol without contrast medium (biparametric MRI) is used with a lower cost per examination, allowing to increase both the number of patients examined and patient comfort The main objective of the project is to assess the contribution of imaging in the screening of clinically significant prostate cancer and to validate the published results in the Czech population, and extend the screening model by the second round of examinations and additional laboratory markers. The secondary aim is to design a subsequent study with a larger number of participants allowing statistical evaluation, similar to the successful breast cancer screening.		'''Study Summary''': Prostate cancer is one of the most common malignancies in the male population with incidence and mortality rates comparable to breast cancer in women, but in contrast, a population screening program that would fulfill all the recommended criteria is not yet available. According to international recommendations, the preventive PSA sampling used in clinical practice is not suitable because of the concurrent detection of clinically insignificant carcinomas in a major proportion of tests. These clinically non-significant cancers make up a significant and increasing proportion with age. Detection of non-significant cancers burdens the health care system and patients with the care that has no positive impact on their health. Current preventive serum prostate-specific antigen (PSA) testing does not distinguish benign hyperplasia and nonsignificant carcinoma from clinically significant cancer. It is therefore not suitable for full-scale screening According to current guidelines, magnetic resonance imaging (MRI) is indicated only in patients with an increased risk of cancer for detection or staging after biopsy and is not used for screening. According to recent studies, MRI has detected an increased proportion of significant cancers in the general population compared to screening based on PSA, while fewer clinically insignificant cancers have been detected. In screening, a shorter examination protocol without contrast medium (biparametric MRI) is used with a lower cost per examination, allowing to increase both the number of patients examined and patient comfort The main objective of the project is to assess the contribution of imaging in the screening of clinically significant prostate cancer and to validate the published results in the Czech population, and extend the screening model by the second round of examinations and additional laboratory markers. The secondary aim is to design a subsequent study with a larger number of participants allowing statistical evaluation, similar to the successful breast cancer screening.
	'''Sponsor''': Masaryk Memorial Cancer Institute		'''Sponsor''': Masaryk Memorial Cancer Institute

Francine: Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to Masaryk Memorial Cancer Institute page '''NCTID''': NCT05603351 '''Title''': Prostate Cancer Screening With Abbreviated MRI Protocol '''Study Summary''': Prostate cancer is one of the most common malignancies in the male population with incidence and mortality rates comparable to breast cancer in women, but in contrast, a population screening program that would fulfill all the recommended criteria is n..."

2023-12-01T20:55:34Z

Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to Masaryk Memorial Cancer Institute page '''NCTID''': NCT05603351 '''Title''': Prostate Cancer Screening With Abbreviated MRI Protocol '''Study Summary''': Prostate cancer is one of the most common malignancies in the male population with incidence and mortality rates comparable to breast cancer in women, but in contrast, a population screening program that would fulfill all the recommended criteria is n..."

New page

{{forpatients}}
{{forproviders}}
{{forresearchers}}
Go back to [[Masaryk Memorial Cancer Institute]] page

'''NCTID''': NCT05603351
'''Title''': Prostate Cancer Screening With Abbreviated MRI Protocol
'''Study Summary''': Prostate cancer is one of the most common malignancies in the male population with incidence and mortality rates comparable to breast cancer in women, but in contrast, a population screening program that would fulfill all the recommended criteria is not yet available. According to international recommendations, the preventive PSA sampling used in clinical practice is not suitable because of the concurrent detection of clinically insignificant carcinomas in a major proportion of tests. These clinically non-significant cancers make up a significant and increasing proportion with age. Detection of non-significant cancers burdens the health care system and patients with the care that has no positive impact on their health. Current preventive serum prostate-specific antigen (PSA) testing does not distinguish benign hyperplasia and nonsignificant carcinoma from clinically significant cancer. It is therefore not suitable for full-scale screening According to current guidelines, magnetic resonance imaging (MRI) is indicated only in patients with an increased risk of cancer for detection or staging after biopsy and is not used for screening. According to recent studies, MRI has detected an increased proportion of significant cancers in the general population compared to screening based on PSA, while fewer clinically insignificant cancers have been detected. In screening, a shorter examination protocol without contrast medium (biparametric MRI) is used with a lower cost per examination, allowing to increase both the number of patients examined and patient comfort The main objective of the project is to assess the contribution of imaging in the screening of clinically significant prostate cancer and to validate the published results in the Czech population, and extend the screening model by the second round of examinations and additional laboratory markers. The secondary aim is to design a subsequent study with a larger number of participants allowing statistical evaluation, similar to the successful breast cancer screening.
'''Sponsor''': Masaryk Memorial Cancer Institute
'''Intervention''': magnetic resonance
'''Start Date''': 2022-05-01
'''Last Updated''': 2022-11-02
'''Number of Patients''': 300
'''Recruitment Status''': RECRUITING
'''Condition''': Prostate Cancer
'''NCTID''': NCT04580251
'''Title''': Ideal Marker for Targeted Axillary Dissection
'''Study Summary''': A multicentre prospective comparative study, comparing the use of various markers (magnetic marker Magseed, iodine seed 125I, carbon suspension) for marking a pathological lymph node in patients with breast carcinoma prior to neoadjuvant therapy and subsequent surgical treatment consisting of targeted axillary dissection.
'''Sponsor''': University Hospital Ostrava
'''Intervention''': Targeted axillary dissection
'''Start Date''': 2021-01-01
'''Last Updated''': 2023-09-07
'''Number of Patients''': 100
'''Recruitment Status''': COMPLETED
'''Condition''': Breast Cancer
'''NCTID''': NCT05348486
'''Title''': FMISO-based Adaptive Radiotherapy for Head and Neck Cancer
'''Study Summary''': Hypoxia occurs in about 80% of head and neck tumors. Based on experimental and clinical data, hypoxia is a useful parameter for pretherapeutic stratification. These radioresistant regions can be detected with FMISO PET/CT. Moreover, hypoxic subvolumes of tumors can be evolving as target volumes for radiotherapy ("dose painting") in hypoxia imaging-based dose escalation.
'''Sponsor''': University Hospital Olomouc
'''Intervention''': Dose escalation
'''Start Date''': 2022-04-20
'''Last Updated''': 2022-05-11
'''Number of Patients''': 120
'''Recruitment Status''': ACTIVE_NOT_RECRUITING
'''Condition''': Head and Neck Cancer
'''NCTID''': NCT03443856
'''Title''': Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
'''Study Summary''': The primary objective of the trial is to investigate if nivolumab plus ipilimumab given as adjuvant treatment improve disease free survival (DFS) in patients with stage Ib-IVa gastric and esophagogastric junction adenocarcinoma and high risk of recurrence (defined by ypN1-3 and/or R1 status) following neoadjuvant chemotherapy and resection Other study objectives * To investigate the safety and effect of adjuvant immunotherapy on long term oncologic outcomes and quality of life of patients in the stud * To correlate nutritional status assessment on outcomes and quality of life of patients
'''Sponsor''': European Organisation for Research and Treatment of Cancer - EORTC
'''Intervention''': Nivolumab and Ipilimumab
'''Start Date''': 2019-07-17
'''Last Updated''': 2023-09-07
'''Number of Patients''': 197
'''Recruitment Status''': ACTIVE_NOT_RECRUITING
'''Condition''': Gastric and Esophagogastric Junction Adenocarcinoma
'''NCTID''': NCT04031677
'''Title''': Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
'''Study Summary''': This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
'''Sponsor''': European Organisation for Research and Treatment of Cancer - EORTC
'''Intervention''': Surgery
'''Start Date''': 2021-01-20
'''Last Updated''': 2023-10-27
'''Number of Patients''': 250
'''Recruitment Status''': RECRUITING
'''Condition''': Retroperitoneal Sarcoma
'''NCTID''': NCT04921553
'''Title''': Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)
'''Study Summary''': This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications.
'''Sponsor''': Centre Leon Berard
'''Intervention''': Data collection and quality of life questionnaire
'''Start Date''': 2021-06-22
'''Last Updated''': 2021-08-02
'''Number of Patients''': 500
'''Recruitment Status''': RECRUITING
'''Condition''': Cancer
'''NCTID''': NCT00388726
'''Title''': E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
'''Study Summary''': The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's Choice (TPC) in patients with locally recurrent or metastatic breast cancer.
'''Sponsor''': Eisai Inc.
'''Intervention''': E7389
'''Start Date''': 2006-11
'''Last Updated''': 2020-01-07
'''Number of Patients''': 762
'''Recruitment Status''': COMPLETED
'''Condition''': Breast Cancer/